Canine atopic dermatitis affects an estimated 10-15% of dogs and is one of the most common reasons for veterinary visits. The category has been transformed by JAK inhibitors and biologics. Zoetis's Apoquel (oclacitinib) reached over $1 billion in cumulative sales since launch, and Cytopoint (lokivetmab) — a monoclonal antibody anti-IL-31 — drove double-digit dermatology franchise growth in 2025. In February 2026 the FDA approved Merck Animal Health's NUMELVI (atinvicitinib), a second-generation JAK1-selective inhibitor positioned as a once-daily first-line therapy with improved tolerability. The competitive race now extends to anti-IL-31 biologics, longer-duration formulations, and novel mechanisms targeting itch pathways. The dermatology category is forecast to grow at high-single-digit rates through 2030.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Veterinary Dermatology Market Size, Growth and Forecast 2025-2030
• Canine Atopic Dermatitis — Disease Burden and Treatment Algorithms
• JAK Inhibitors — Apoquel, NUMELVI, and Pipeline Candidates
• Anti-IL-31 Biologics — Cytopoint and Next-Generation mAbs
• Topical Corticosteroids and Antimicrobial Therapies
• Allergen Immunotherapy and Diagnostic Approaches
• Feline Allergic Dermatitis — Distinct Therapeutic Approaches
• Bacterial Skin Infections and Antimicrobial Stewardship
• Regulatory Landscape — FDA CVM, EMA Approval Pathways
• Investment and Partnership Opportunities — Licensing, Co-Development
• Market Challenges and Risks — Generic Entry, Treatment Resistance
Table of Contents
1. Executive Summary
2. Market Overview
3. Veterinary Dermatology Market Size, Growth and Forecast 2025-2030
4. Canine Atopic Dermatitis
5. JAK Inhibitors
6. Anti-IL-31 Biologics
7. Topical Corticosteroids and Antimicrobials
8. Allergen Immunotherapy
9. Feline Allergic Dermatitis
10. Bacterial Skin Infections
11. Regulatory Landscape
12. Regional Analysis
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Veterinary Dermatology Market Size and Forecast 2025-2030
Table 2. Atopic Dermatitis Prevalence and Treatment Pathway by Severity
Table 3. JAK Inhibitor Sales — Apoquel, NUMELVI, Pipeline
Table 4. Anti-IL-31 Biologic Sales — Cytopoint and Pipeline Candidates
Table 5. Topical Therapy Sales by Brand 2023-2025
Table 6. Allergen Immunotherapy Market by Supplier
Table 7. Feline Dermatology Therapeutics — Sales by Indication
Table 8. Antimicrobial Skin Therapeutics — Sales and Stewardship Impact
Table 9. FDA CVM and EMA Approval Timeline 2024-2028
Table 10. Competitive Positioning by Mechanism of Action
Companies Profiled
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
Merck Animal Health
Vetoquinol
Virbac
Zoetis
